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1Metabolic syndrome (MetS) affects one in 4 people and is a major cause of coronary artery disease and type 
2 diabetes mellitus (T2DM).1 MetS genetic determinants 
have been successfully elucidated in the spontaneously hy-
pertensive rat (SHR), an established model of human pol-
ygenic MetS.2 Our previous studies identified Camk2n1 
as a cis-regulated expression quantitative trait locus (cis-
eQTL) in left ventricle (LV) and epididymal adipose tissue 
(EAT),3 and as a quantitative trait transcript that signifi-
cantly positively correlates with relative fat pad weight 
(r2=0.67, P(adj)=0.0002) and adipocyte volume (r2=0.69, 
P(adj)=0.0002).4 Furthermore, Camk2n1 is close to the peak 
logarithm of the odds (to the base 10) score in QTLs for sys-
tolic blood pressure(BP; Bp292, Bp180, 433, and 441 Kb 
from peak) and relative LV weight (Cm24 and 441 Kb from 
peak) and resides in a QTL for T2DM (Niddm30).5
Camk2n1 has been reported through in vitro and in vivo 
peptide inhibition studies to be a specific inhibitor of CaMKII 
(Ca2+/calmodulin-dependent kinase II),6 an enzyme activated 
by Ca2+/calmodulin binding, which regulates multiple signal-
ing pathways that control vascular tone,7 in vitro adipogen-
esis,8 and insulin-stimulated glucose uptake.9 However, the in 
vivo functions of endogenous Camk2n1 in cardiometabolic 
disease have not been studied directly, whereas experimental 
inhibition of CaMKII has been extensively studied because 
of the strong association between CaMKII hyperactivity, LV 
hypertrophy, and heart failure in humans.10 CaMKII inhibi-
tion has been induced experimentally using synthetic and 
transgenic CaMKII inhibitors. These studies have shown 
that such inhibitors can protect from Ang II (angiotensin II)–
induced hypertension7 and LV hypertrophy.11 However, these 
CaMKII inhibitors have known off-target effects independent 
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that control metabolic syndrome traits and merits further investigation as a therapeutic target in humans.  (Hypertension. 
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of CaMKII and may not mimic fully endogenous Camk2n1 
functions.12
In other studies, knockout of CaMKII has been shown to 
protect from pressure-overload LV dysfunction but not prevent 
LV hypertrophy.13 CaMKII knockout improved hepatic insulin 
signaling in obese mice, while enhanced CaMKII activation 
has been shown to induce hyperinsulinemia and glucose intol-
erance.14 Taken together, these data suggest a potential causal 
role for Camk2n1 in cardiometabolic disease.
Here, we test the hypothesis that Camk2n1 regulates car-
diometabolic traits by generating a Camk2n1 knockout in the 
SHR model of MetS.
Methods
The authors declare that all supporting data are available within the 
article and detailed methods and supplementary results in the online-
only Data Supplement.
Rats
SHR-Camk2n1−/− knockout rats (referred to hereafter as Camk2n1−/− 
rats) were generated on an SHR/NCrl background (Charles River, 
Margate, United Kingdom), containing a 38bp deletion in exon 1 of 
Camk2n1 confirmed by whole genome sequencing, polymerase chain 
reaction, and Immunoblot (Figure S1A through S1C in the online-
only Data Supplement). All procedures were performed in accord-
ance with UK Home Office regulations.
Human Participants
Visceral adipose tissue was obtained intraoperatively following eth-
ical approval from 28 lean, obese, and obese type 2 diabetic subjects 
who were attending the Royal Infirmary of Edinburgh for elective 
abdominal surgery for nonmalignant disease (Lothian NRS Human 
Annotated Bioresource [15/ES/0094]).
Statistical Analysis
Unpaired t tests, 1-way, or 2-way ANOVA followed by Fisher least 
significant difference post hoc test were used to assess differences 
between SHR, Camk2n1−/− and treatment, and differences between 
lean, obese, and obese diabetic subjects. All statistics were performed 
using Minitab Express (v1.5.1).
Results
Camk2n1 Knockout Rat
We generated a Camk2n1−/− rat using zinc finger nuclease that 
created a 38 bp deletion in exon 1 of Camk2n1 confirmed by 
a polymerase chain reaction, Sanger sequencing, and whole 
genome sequencing (Figure S1A). Truncation of the transcript 
and absence of Camk2n1 protein were confirmed by a poly-
merase chain reaction and immunoblot, respectively (Figure 
S1B and S1C).
Blood Pressure
To determine the cardiovascular consequences of Camk2n1 
deletion, we measured BP in SHR and Camk2n1−/− rats. Mean 
systolic BP (−Δ12 mm Hg, P<0.001) and diastolic BP (−Δ10 
mm Hg, P<0.005) BPs were significantly lower in Camk2n1−/− 
than SHR, and although heart rate was similar (SHR=299±3 
Camk2n1−/−=305±6, P>0.05), rate pressure product was 
reduced significantly by 5% (Figure 1A through 1C).
To test whether lower BP in Camk2n1−/− rats was as-
sociated with altered vasodilatory mechanisms, we tested 
in vivo vasoreactivity to acetylcholine in the presence and 
absence of Nω-Nitro-L-arginine methyl ester hydrochloride 
or Ang(1–7) antagonist A-779 and analyzed the ACE2 (an-
giotensin II–converting enzyme)-Ang-(1–7)-Mas pathway. 
Area under the blood pressure curve responses to the low-
est level of acetylcholine infusion were similar in SHR and 
Camk2n1−/− (Figure 1D). At higher doses of acetylcholine, 
Camk2n1−/− had a similar response in the presence or ab-
sence of Nω-Nitro-L-arginine methyl ester hydrochloride, 
whereas responses in SHR treated with Nω-Nitro-L-arginine 
methyl ester hydrochloride were reduced (Figure 1D). These 
changes were associated with increased renal ACE2 ac-
tivity and Ang (1–7) concentrations in Camk2n1−/− kidney 
and serum (Figure 1D; Table). In addition, renal and serum 
eNOS (endothelial nitric oxide synthase) and serum ni-
trate levels were elevated in Camk2n1−/− compared with 
SHR (Figure 1E; Table). Conversely, CaMKII activity was 
reduced by 50% (Figure 1F). A-779 did not affect BP modu-
lation (P>0.05, Figure S2E).
In Camk2n1−/− rats, kidney wet mass was reduced by 4%, 
but no differences in hypertension-related vascular damage 
or kidney function markers were observed (Figure S2A and 
S2B; Table).
LV Mass
To determine the effects of Camk2n1 knockout on LVH, we 
investigated LV structure and function at baseline and with 
isoproterenol-induced (CaMKII-associated) hypertrophy in 
SHR and Camk2n1−/− rats.
LV mass at baseline was reduced by 9% in Camk2n1−/− 
compared with SHR, whereas baseline heart mass was similar 
(Figure 2A and 2B). Histological signs of inflammation and 
fibrosis, blood vessel and cardiomyocyte density and mor-
phology in LV were similar for both genotypes (Figure S2C 
and S2D).
To test whether Camk2n1 deficiency would protect against 
isoproterenol-stimulated LVH, we performed a 72 hours iso-
proterenol hypertrophic challenge. Isoproterenol treatment 
caused similar increases in heart mass and rate and reductions 
in BP in SHR and Camk2n1−/− (Figure 2A and 2B; Figure S3A 
through S3C). However, rate pressure product increased in 
SHR only (Figure 2C).
CaMKII activity and hypertrophy-related transcripts 
Acta, Actc, and Nppb were assessed in LV. CaMKII activity 
was reduced by 23% in Camk2n1−/− compared with SHR LV 
(Figure 2D). Acta1 transcripts were 1.5-fold greater in saline-
treated Camk2n1−/− than in SHR, and after treatment with iso-
proterenol, Acta and Actc increased in SHR LV only, thereby 
increasing the ratio of Acta1:Actc1 in SHR compared with 
Camk2n1−/− LV (Figure 2E). Camk2n1 deletion did not affect 
Nppb expression (Figure 2F).
Insulin Sensitivity
To establish a function for Camk2n1 in glucose metabolism, 
we measured the effectiveness of endogenous insulin to stim-
ulate peripheral tissues glucose uptake, after an oral glucose 
bolus. Fasting plasma glucose concentrations in Camk2n1−/− 
were significantly lower than SHR (P<0.01; Figure 3A), al-
though, area under the glucose curve was similar (P>0.05). 
Plasma insulin concentrations at t0 and t30–t60 minutes and area 
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under the insulin curve following glucose bolus were signifi-
cantly reduced together with homeostatic model assessment of 
insulin resistance (SHR, 1.22±0.06, Camk2n1−/−, 0.51±0.06, 
P=0.00001) in Camk2n1−/− compared with SHR (Figure 3A).
Adiposity
To assess a causal role for Camk2n1 in adiposity, we 
assessed adipose tissue mass, morphology, and adipo-
cyte function of SHR and Camk2n1−/− fat pads. Relative 
masses of visceral (EAT, mesenteric, and retroperitoneal 
adipose tissue) and brown adipose tissue were significantly 
reduced in Camk2n1−/− compared with SHR, despite sim-
ilar growth rate and total body mass (P>0.05; FigureS4A) 
with an overall 23% reduction (P=0.004) in total relative fat 
mass (Figure 3B). Subcutaneous fat mass was unaltered by 
Camk2n1 deletion (Figure 3B). Morphometric assessment of 
EAT showed that the reduced fat mass in Camk2n1−/− rats 
was associated with a reduction in adipocyte number rather 
than adipocyte volume (Figure 3B).
To determine whether Camk2n1 knockout altered CaMKII 
activity, visceral fat respiration, and whole-body adipokine 
production, we analyzed CaMKII activity, cellular energetics 
in epididymal adipocytes, and quantified serum concentrations 
of high molecular weight adiponectin and leptin in SHR and 
Camk2n1−/− rats. EAT CaMKII activity was similar in SHR 
and Camk2n1−/− rats (Figure 3D). Mitochondrial oxygen con-
sumption: basal, ATP-linked, maximal, and leak respiration 
were similar in SHR and Camk2n1−/− adipocytes (Table S3). 
However, we found a 20% decrease (P=0.038) in circulating 
HMW adiponectin and a significant 70% decrease (P=0.01) 
in circulating leptin (Table). Given the reduction in fat mass 
and circulating leptin, we assessed food intake, body temper-
ature, and locomotor activity as indicators of energy homeo-
stasis in SHR and Camk2n1−/− rats. Food intake was reduced 
in Camk2n1−/− from 6 to 8 weeks age, whereas from 9 to 10 
weeks of age, food intake was greater compared with SHR 
(Figure 3D); across the 6 to 10 week period, average food in-
take was not significantly different (P>0.05; Figure 3D, inset). 
There were no significant differences in body temperature and 
locomotor activity (P>0.05; Figure S4B and S4C).
In Vitro Camk2n1 Knockdown in 3T3-L1 
Adipocytes
To establish whether Camk2n1 deficiency reduced adipo-
genic capacity, we knocked down Camk2n1 expression in 
mouse 3T3-L1 fibroblasts. Camk2n1 knocked down of 
85% to 96% was confirmed from day 1 to 9 following lipo-
fectamine treatment (Figure S5A) and was associated with 
a significant reduction in lipid formation assessed by oil red 
O staining intensity and reduction in the proportion of cells 
Figure 1. Cardiovascular physiology and 
in vivo vasoreactivity in spontaneously 
hypertensive rat (SHR) and Camk2n1-/- rats. 
A, Systolic (SBP) and (B) diastolic blood 
pressures (DBP) and (C) rate pressure product 
(RPP). D, In vivo physiological analysis of 
ACE2 (angiotensin II–converting enzyme)-Ang-
(1–7)-Mas signaling, area under the BP curve 
(AUCBP) against acetylcholine (ACh) in the 
presence or absence of Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME) with 
renal angiotensin II–converting enzyme (ACE2) 
activity and angiotensin-(1–7) concentrations. 
E, Renal eNOS (endothelial nitric oxide 
synthase) and serum nitrate concentrations. 
F, Renal CaMKII activity. Mean±SEM, n=13/
group for telemetry, n=7–9/group for renal and 
serum measurements. Significant differences 
by genotype (SHR and Camk2n1−/−) (*P<0.05, 
**P<0.005, and ***P<0.001) and treatment 
(†P<0.05).
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containing lipids by day 9 (P<0.05; Figure 3E). Markers of 
adipogenesis, Cebpa and Pparg were significantly altered by 
Camk2n1 deficiency. Cebpa and Pparg expression increase 
from day 1 to 9 in scramble treated cells, whereas expres-
sion of these genes was significantly perturbed by Camk2n1 
siRNA by 63% (P<0.01) and 80%(P<0.001) on day 9, re-
spectively (Figure 3F). By day 9, the mature adipocyte mark-
ers Lep and Adipoq in siRNA-treated cells were similar to 
control (Figure S5B).
Transcriptomics
The molecular networks regulated by Camk2n1 were de-
fined by weighted gene coexpression analysis (WGCNA) 
of the SHR and Camk2n1−/− LV and EAT transcriptomes. 
Differential expression was validated in LV and EAT by com-
paring expression of 12 genes (Table S4).
In LV, there were 192 differentially expressed genes 
(DEGs), 118 DEGs were ≥2-fold different between geno-
types (P
adj<0.05; Figure 4A; Table S5). Of the most significant 
DEG, Kirrel3, Fabp4, Atf3, Capn3, Hdac4, and Plcb4 control 
cardiomyocyte size and function, whereas Cfi, Irak3 Rnf144b, 
and Hspa8 regulate inflammatory processes. WGCNA of the 
LV transcriptome defined 8 modules with significant correla-
tion to Camk2n1 (Figure 4B). Kyoto Encyclopedia of Genes 
and Genomes functional enrichment analysis of these mod-
ules showed that Camk2n1−/− LV are significantly enriched 
for cell function and maintenance, intracellular signaling, 
metabolism, and antigen presentation networks (Table S6). 
GO analysis showed that across modules, there were con-
sistent themes relating to transcript and protein regulation 
(Table S7). Levels of FABP4 (fatty acid binding protein 4) 
in LV, a protein that regulates several enriched pathways, was 
reduced in Camk2n1−/− compared with SHR (Figure 4C).
In EAT, there were 129 DEGs after adjustment for mul-
tiple testing; 90% of the most DEGs (≥2-fold) were downregu-
lated with 20% associated with metabolic pathways (Pla2g2a, 
P4ha3, Pla2g5, Slc39a8, Pcdh7, and Gcnt2) and cell prolif-
eration (Cldn15, Fgf9, Diaph3, and Mki67; Figure 4D; Table 
S8). WGCNA of the EAT transcriptome defined 8 modules 
correlated significantly with Camk2n1 (Figure 4E; Table S9). 
Five modules were significantly enriched in Camk2n1−/− EAT 
for KEGG pathways regulating cell maintenance and survival, 
and innate immunity and antigen presentation (Table S9), with 
transcript regulation and immune defense GO terms signifi-
cantly enhanced (Table S10).
Soluble phospholipase A2 activity, which regulates 
adipogenesis and apoptosis, was reduced significantly in 
Camk2n1−/− compared with SHR (Figure 4F).
Human CAMK2N1 Cis-eQTL and Cardiometabolic 
Trait Analysis
We analyzed human data from the GTEx and Type 2 
Diabetes Knowledge Portals to investigate whether sequence 
variants that increase/decrease CAMK2N1 expression were 
associated with cardiometabolic traits. We identified 263 cis-
eQTLs regulating CAMK2N1 (Table S11). The most signifi-
cant single nucleotide polymorphism regulating CAMK2N1 
were found in Adipose–Visceral (VAT), in which there were 
51 in total for this tissue. To test whether cis-eQTLs for 
CAMK2N1 are enriched in VAT, we compared 1000 sets of 
263 cis-eQTLs not associated with CAMK2N1. There were 
21.7% of CAMK2N1 cis-eQTLs in VAT, compared with 
20.7% to 21.0% non-CAMK2N1 cis-eQTLs in VAT in the 
1000 sets of non-CAMK2N1 cis-eQTLs (Figure S6).
Of the CAMK2N1 cis-eQTLs in VAT, 44 were significantly 
associated with cardiometabolic traits in the knowledge portals 
(Table S12). T2DM was the most frequent disease trait, linked 
to 39 variants (effect size range: −0.43 to 0.40, P
adj=0.048–
0.0052; Figure 5A), followed coronary artery disease linked to 
27 variants (effect size range: −0.43 to 0.35, P
adj=0.047–0.016; 
Figure 5B). All variants that are associated with CAMK2N1 
downregulation (negative effect size), are also associated 
with significant disease risk reduction, whereas variants that 
are associated with CAMK2N1 upregulation (positive effect 
size), are associated with increased disease risk (Figure 5A 
and 5B; Table S11). To test whether CAMK2N1 cis-eQTLs 
are enriched for cardiometabolic traits, we determined the as-
sociation to traits of VAT cis-eQTLs in a randomly selected set 
of 263 cis-eQTLs not associated with CAMK2N1 (Table S13). 
There was a significantly greater number of CAMK2N1 cis-
eQTLs associated with T2DM, coronary artery disease, and 
VAT volume than cis-eQTLs not associated with CAMK2N1 
(Table S14).
To establish the effect size of CAMK2N1 expression on 
visceral fat mass (not reported in the knowledge portals, 
we quantified CAMK2N1 expression in human visceral fat 
Table. Serum and Urinary Biochemical Analyses
Fluid Parameter SHR Camk2n1−/−
Serum Calcium, mmol/L 2.34±0.01 2.41±0.02*
Chloride, mmol/L 100.0±0.4 99.6±0.6
Potassium, mmol/L 5.07±0.06 5.12±0.04
Sodium, mmol/L 147±0.3 147±0.5
Cholesterol, mmol/L 1.20±0.05 1.29±0.03
Triglycerides, mmol/L 0.28±0.01 0.29±0.01
Creatinine 53.6±1.0 54.9±0.7
Urea 10.6±0.4 10.6±0.2
Adiponectin HMW, ng/mL 2.98±0.13 2.39±0.09*
Leptin, ng/mL 1.93±0.48 0.56±0.08†
eNOS, pg/mL 25±2 37±2*
Ang-(1–7), pg/mL 78±6 101±6†
Urine Potassium, mmol/L 109±18 95±12
Sodium, mmol/L 134±27 112±13
Urea, mmol/L 72±26 77±24
Uric acid, mmol/L 0.99±0.17 0.77±0.16
Creatinine, mmol/L 9.99±2.36 7.06±9.63
Protein, g/L 1.76±0.39 1.17±0.16
Mean±SEM, n=10/group for analyses; n=5–7/group for adiponectin, leptin, 
eNOS, nitrate, and angiotensin-(1–7) (Ang-(1–7). Ang indicates angiotensin; 
eNOS, endothelial nitric oxide synthase; HMW, high molecular weight; and SHR, 
spontaneously hypertensive rat.
*P<0.01.
†P<0.05.
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samples and found that compared with lean subjects, obese 
nondiabetics, and obese diabetics had a significantly greater 
body mass index, weight, and fat mass compared with lean 
subjects; although, BP across groups was not significantly 
different (Table S15). CAMK2N1 expression in visceral fat 
was increased significantly by 1.82- to 2.76-fold in obese dia-
betic and nondiabetic subjects, respectively, compared to lean 
nondiabetics (effect size, obese =1.23, P=0.02, obese diabetic 
=1.56, P<0.005), but between obese groups, expression was 
similar (P>0.05; (Figure 5A). Regression analysis showed 
that CAMK2N1 expression in visceral fat correlated signifi-
cantly with body mass index (Figure 5D) and absolute fat 
mass (r2=0.34, P=0.0069).
Discussion
The major results in this study demonstrate that Camk2n1 
knockout in SHR reduced CaMKII activity in the kidney and 
LV, but not in adipose tissue and that these changes lead to 
profound alterations in the cardiometabolic phenotype of the 
Camk2n1−/− rat. Compared with SHR, Camk2n1−/− rats had 
lower BP and increased vascular reactivity and lower LV mass 
and rate pressure product. Camk2n1 knockout increased in-
sulin sensitivity, whereas visceral fat mass in vivo and adipo-
genic capacity in vitro were decreased. These data support 
the previous eQTL and linkage studies in rat RI strains that 
showed strong associations between Camk2n1 and these car-
diometabolic traits.3,4
Figure 2. Cardiac phenotype in spontaneously 
hypertensive rat (SHR) and Camk2n1−/− rats. A, 
Heart and (B) left ventricle (LV) wet masses. C, 
Rate pressure product (RPP). D, LV CaMKII (Ca2+/
calmodulin-dependent kinase II) activity. Average 
transcript levels normalized to hypoxanthine-
guanine phosphoribosyltransferase, Hprt for (E) 
α-skeletal actin, Acta, α-cardiac actin, Actc, the 
Acta:Actc ratio and (F) natriuretic protein b, Nppb. 
Mean±SEM n=5–7/group. Significant differences 
by genotype (SHR and Camk2n1−/−) (*P<0.05, 
**P<0.01, and ***P<0.001) and treatment (†P<0.05, 
††P<0.01, and †††P<0.001).
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We show that reduced BP and increased vasoreactiv-
ity are associated with enhanced ACE2-Ang-(1–7)-Mas 
signaling in Camk2n1−/− rats. In LV, CaMKII-associated 
prohypertrophic and upregulation antihypertrophic compo-
nents of cell cycle were downregulated, specifying mecha-
nisms for reduced LV mass, whereas in EAT, diminished 
pro-obesogenic cell cycle pathways and classical comple-
ment associated with insulin resistance provide mechanistic 
insights into reduced adiposity and ameliorated insulin sen-
sitivity of Camk2n1−/− rats. In human visceral fat, we found 
that CAMK2N1 expression correlated with fat mass and 
body mass index, in keeping with previous reports of 34 
cis-eQTLs (GTex Portal) that associated significantly with 
increased CAMK2N1 expression and elevated risk of T2DM 
and coronary artery disease.
Experimental inhibition of CaMKII has been investigated 
to develop new treatments for hypertension and cardiac hy-
pertrophy.10–12,15 In addition, indirectly, these and other studies 
have investigated the function of Camk2n1 while also testing 
CaMKII function. However, because of a number of off-target 
effects, including regulation of calcium signaling, masking 
docking sites on CaMKII, and inhibiting CaM-associated and 
other kinases, associated with KN-92, KN-93, autocamtide-
derived inhibitory peptide (AC3-I), and CaMKIIN-tides, used 
in these inhibitor studies, there is an incomplete understanding 
of Camk2n1 function and its regulation of CaMKII.12 
Furthermore, these inhibitory peptides are based on the inhib-
itory domain of CAMKIIN/Camk2n2, which has a different 
expression pattern and is likely conformationally and func-
tionally distinct from endogenous Camk2n1. In our study, we 
show that endogenous Camk2n1 is required for full activity of 
CaMKII in kidney and LV but is dispensable for CaMKII ac-
tivity in adipose tissue. We propose that the cardiorenal phys-
iological and molecular effects of Camk2n1 deletion are, in 
part, likely determined by reduced CaMKII activity, but may 
also be due, at least in adipose tissue, to CaMKII-independent 
functions of Camk2n1.
Hypertension, like other features of MetS, has a pol-
ygenic basis and is controlled by multiple genetic variants 
in both rats and humans. For example, BP QTLs have been 
found on all rat chromosomes,16 just as GWAS hits for hyper-
tension reside across all human chromosomes.17 Moreover, 
there is good agreement between rat BP QTLs and genes, and 
their syntenic regions and orthologs in humans, with the like-
lihood that the networks regulating BP are conserved across 
species.16 Hypertension can be mitigated by NO-mediated 
vasodilation through the ACE2-Ang(1–7)-Mas axis; in 
humans, ACE2 and NOS3 variants modulate BP, whereas 
renal eNOS deficiency in SHR, or ACE2 deletion in mice, 
contribute to hypertension and hypertension-related renal 
Figure 3. Metabolic phenotype in 
spontaneously hypertensive rat (SHR) and 
Camk2n1−/− rats. A, Blood glucose and 
insulin curves during oral glucose tolerance 
testing. B, Relative adipose tissue wet 
masses for subcutaneous (SAT), epididymal 
(EAT), retroperitoneal fat (RAT), mesenteric 
fat (MAT), and brown adipose tissues (BAT), 
EAT adipocyte volume and number. C, EAT 
CaMKII (Ca2+/calmodulin-dependent kinase 
II) activity. E, Representative wells and light 
micrograph images (scale bar 200 µm) of 
3T3-L1 adipocytes and percentage of cells 
with or without lipid accumulation. F, Cebpa 
and Pparg transcript levels 0, 1, 4, and 9 d 
after knockdown. In vivo: mean±SEM n=7/
group, significant differences (*P<0.05, 
**P<0.01, and ***P<0.001). In vitro mean±SEM 
n=3 independent experiments, significant 
differences (†P<0.05, ††P<0.01, and 
†††P<0.001).
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damage.18–21 CaMKIIN transfection in vitro into endothelial 
cells reduced Ca2+/CaM binding to eNOS and decreased NO 
production following bradykinin stimulation,22 whereas in 
vivo transgenic overexpression of CaMKIIN or AC3-I did not 
alter baseline BP nor NO-dependent vasodilation,23 only par-
tially protecting from Ang II–induced hypertension, without 
affecting CaMKII overactivity.7 The relationship between 
CaMKII and ACE2 has not been elucidated. However, in our 
study, Camk2n1 deletion reduced renal CaMKII activity, but 
increased renal ACE2 and eNOS, and their respective prod-
ucts, Ang-(1–7) and NO, which may, in part, be responsible 
for the lower BP in Camk2n1−/−. ACE2, eNOS, and CaMKII 
are regulated by Ca2+/CaM binding24,25; therefore, Camk2n1 
may regulate the binding association of Ca2+/CaM with these 
enzymes, thereby affecting their activation and vasodilatory 
capacity.
Figure 4. Weighted coexpression network analysis (WGCNA) of spontaneously hypertensive rat (SHR) and Camk2n1−/− left ventricle (LV) and epididymal 
adipose tissue (EAT) transcriptomes. A, Heat map of significantly differentially expressed genes (>2-fold) (DEG) in LV. B, Significantly enriched modules in LV 
correlated with Camk2n1. C, LV FABP4 (fatty acid binding protein 4) concentrations. D, Heat map of DEG (>2-fold) in EAT. E, Significantly enriched modules 
in EAT correlated with Camk2n1. F, Serum soluble phospholipase A2 (sPLA2) activity. Transcriptomics n=4 rat/tissue; in vivo validation n=9. Mean±SEM, 
significant differences (*P<0.05 and **P<0.01).
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CaMKII overactivity in humans with hypertension or 
T2DM is considered a cause of pathological LVH and heart 
failure.10 We found that Camk2n1 deletion reduced cardiac 
CaMKII activity and LV mass in SHR and conferred partial 
protection from increased myocardial load. Thus, our data sup-
port previous studies showing reduced CaMKII activity ame-
liorates LV remodeling, but that this occurs through Camk2n1 
deficiency. Our WGCNA defined altered hypertrophic path-
ways associate with Camk2n1 knockout. For example, the 
cell cycle pathway that included inhibitors Cdkn3 and E2f8 
was upregulated in Camk2n1−/− LV.26,27 Furthermore, Fabp4/
FABP4 were downregulated in Camk2n1−/− LV and have been 
shown to promote cardiac hypertrophy in mice and regulate 
AMPK signaling, actin cytoskeleton, and oxidative phospho-
rylation,28 all of which were associated with Camk2n1 dele-
tion in our study.
Together, these changed pathways indicate mechanisms 
by which Camk2n1 knockout has reduced LV mass and is pro-
tected from stress-related rate pressure product increases and 
remodeling through CaMKII modulation.
Insulin resistance, a key factor in MetS, was ameliorated 
in Camk2n1−/− rats and occurs independently of CaMKII in 
adipose tissue. Improved insulin sensitivity is associated in 
humans with increased circulating NO20 and Ang-(1–7),29 
and reduced leptin and visceral adiposity,30 all of which are 
features of Camk2n1−/− rats. In addition, improved insulin 
sensitivity in SHR by Camk2n1 deletion, mirrors the connec-
tion in humans, we found between cis variants that decrease 
CAMK2N1 expression and are associated with increased in-
sulin sensitivity.
In humans, we showed that CAMK2N1 was reduced in vis-
ceral fat from lean compared with obese subjects, consistent 
with a previous study showing CAMK2N1 upregulation in 
obese compared with lean Pima Indians.31 This is analogous to 
the reduced visceral fat and CaMKII-independent adipogen-
esis we have observed in Camk2n1−/− rats. This is distinct from 
nonspecific CaMKII inhibitor studies suggesting CaMKII reg-
ulation of adipogenesis in vitro.8,12
Adipokine production is determined by adipocyte mat-
uration, hypertrophy, and fat mass.32 Therefore, the reduced 
adiposity in Camk2n1−/− rats is a likely cause of reduced adi-
pokine production. Circulating adiponectin in humans has 
been found to correlate inversely with insulin resistance and 
T2DM.33 However, this relationship is inconsistent, with other 
studies that found elevated adiponectin increased T2DM risk 
and CVD mortality.34,35
WGCNA of the adipose transcriptome defined CaMKII-
independent alterations in obesity- and MetS-related cell 
cycle, classical complement, and apoptosis pathways in 
Camk2n1−/− rats. For example, downregulation in Camk2n1−/− 
EAT of Pla2g5 and Pla2g2a and reduced soluble phospholi-
pase A2 activity supports the amelioration in MetS phenotypes 
in Camk2n1−/− rats, as Pla2g5 is upregulated in obese adipose 
tissue and promotes leptin secretion, whereas Pla2g2a is caus-
ally related to obesity and MetS.30,36 Moreover, soluble phos-
pholipase A2 has been shown to promote adipogenesis and 
apoptosis associated with obesity.30 Apoptosis is an unlikely 
cause of reduced adiposity in Camk2n1−/− rats as proapoptic 
genes (Baiap2l1/Birc5, Dsg2, and Pcdh7) were downregu-
lated. Alternatively, reduced proliferation is suggested by 
upregulation of Cdkn1a/p21 in Camk2n1−/− EAT, which has 
been shown elsewhere to prevent obesity and adipocyte hy-
perplasia,37 and downregulation of Rbl1/p107 and Cdk1 that 
have been shown by others to be pro-obesogenic and upregu-
lated in obesity.38 Furthermore, upregulation of Id3 and down-
regulation of C1s and C4 provide additional mechanisms 
for reduced adiponectin production,39 reduced adiposity, and 
increased insulin sensitivity.32,40
Figure 5. Expression quantitative trait locus 
(eQTLs) that correlate with cardiometabolic 
disease traits and CAMK2N1 expression in 
human visceral fat. A, Variants in the GTex 
portal that alter CAMK2N1 expression (defined 
by effect size) and correlate significantly with 
coronary artery disease (CAD). B, Variants in 
the GTex portal that alter CAMK2N1 expression 
(effect size) and correlate significantly with type 
2 diabetes mellitus adjusted for body mass 
index (T2DM adjBMI). C, CAMK2N1 expression 
(normalized to ACTB) in visceral fat from lean, 
obese, and obese+T2DM subjects. Regression 
analysis: relative CAMK2N1 expression in 
visceral fat with BMI. Mean±SEM n=10 lean, 9 
obese, 9 obese+T2DM. Significant differences 
between lean and obese or obese+T2DM 
(*P=0.02 and **P<0.005). OR indicates odds 
ratio.
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Perspectives
This is the first study to report that in vivo deletion of 
Camk2n1 diminishes CaMKII activity in kidney and heart, 
without affecting adipose CaMKII activity, and that Camk2n1 
deletion causes widespread ameliorations in cardiovascular 
and metabolic phenotypes. Camk2n1 knockout in SHR, ame-
liorated multiple pathophysiological phenotypes including 
hypertension, LV mass, insulin sensitivity, and visceral adi-
posity, associated with reduced cardiorenal CaMKII activity 
and independent of adipose CaMKII activity. Together with 
our demonstration that visceral fat CAMK2N1 expression 
increased in obese subjects and correlated with adiposity 
and our analysis of cis-acting variants that regulate human 
CAMK2N1 and MetS traits, we conclude that Camk2n1 regu-
lates multiple cardiovascular and metabolic processes, both 
dependently and independently of CaMKII, suggesting that 
endogenous Camk2n1/CAMK2N1 may not function exclu-
sively as an inhibitor of CaMKII and requires a reappraisal of 
existing studies that have used nonspecific CaMKII inhibitors 
proposed to mimic Camk2n1 function. Furthermore, our data 
suggest that therapeutic targeting of CAMK2N1 may allow 
amelioration of MetS features in humans.
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What Is New?
•	Camk2n1 negatively regulates blood pressure, left ventricle mass, and 
insulin sensitivity and is required for full adipogenic capacity in the spon-
taneously hypertensive rat.
What Is Relevant?
•	Camk2n1 deletion has effects on multiple organ systems: lowering blood 
pressure and reducing renal CaMKII (Ca2+/calmodulin-dependent ki-
nase II) activity, which is associated with increased ACE2 (angiotensin 
II–converting enzyme)-Ang-(1–7)-Mas activity, enhancing nitric oxide-
related vasoreactivity; in the left ventricle, Camk2n1 deletion reduced 
cardiac CaMKII activity, downregulating hypertrophy-related pathways, 
and preventing stress-induced increased myocardial load; and in visceral 
fat, Camk2n1, improved insulin sensitivity and reduced adipogenesis, by 
downregulating cell cycle pathways, independent of CaMKII.
Summary
Camk2n1 regulates multiple organ systems associated with meta-
bolic syndrome, and its ablation improved MetS features in sponta-
neously hypertensive rat. In humans, visceral fat CAMK2N1 expres-
sion correlated with adiposity, and SNPs that regulate CAMK2N1 
expression are associated with coronary artery disease and type 2 
diabetes mellitus.
Novelty and Significance
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